- Home
- AWH vs RLMD Comparison
AWH vs RLMD Comparison
Compare AWH & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AWH
- RLMD
- Stock Information
- Founded
- AWH 1993
- RLMD 2004
- Country
- AWH United States
- RLMD United States
- Employees
- AWH N/A
- RLMD N/A
- Industry
- AWH Medical/Dental Instruments
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- AWH Health Care
- RLMD Health Care
- Exchange
- AWH Nasdaq
- RLMD Nasdaq
- Market Cap
- AWH 10.5M
- RLMD 11.5M
- IPO Year
- AWH N/A
- RLMD N/A
- Fundamental
- Price
- AWH $0.50
- RLMD $0.37
- Analyst Decision
- AWH Buy
- RLMD Hold
- Analyst Count
- AWH 2
- RLMD 4
- Target Price
- AWH $4.40
- RLMD $4.25
- AVG Volume (30 Days)
- AWH 100.3K
- RLMD 942.1K
- Earning Date
- AWH 11-14-2024
- RLMD 03-18-2025
- Dividend Yield
- AWH N/A
- RLMD N/A
- EPS Growth
- AWH N/A
- RLMD N/A
- EPS
- AWH N/A
- RLMD N/A
- Revenue
- AWH $8,963,000.00
- RLMD N/A
- Revenue This Year
- AWH $11.87
- RLMD N/A
- Revenue Next Year
- AWH $79.10
- RLMD N/A
- P/E Ratio
- AWH N/A
- RLMD N/A
- Revenue Growth
- AWH N/A
- RLMD N/A
- 52 Week Low
- AWH $0.38
- RLMD $0.34
- 52 Week High
- AWH $5.65
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- AWH 27.14
- RLMD 25.62
- Support Level
- AWH $0.38
- RLMD $0.36
- Resistance Level
- AWH $0.79
- RLMD $0.49
- Average True Range (ATR)
- AWH 0.07
- RLMD 0.06
- MACD
- AWH -0.02
- RLMD 0.08
- Stochastic Oscillator
- AWH 27.91
- RLMD 10.06
About AWH Aspira Women's Health Inc.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.